Replies to post #249508 on Biotech Values

[vinmantoo]

The company seems to be emphasizing RSV which suggests a 235 partnership is not imminent.

I think it is too soon to discount a partnership but you may be right that the focus on RSV could reflect that a partnership isn't imminent. On the other hand, unlike a partnership, the RSV drugs are fully in ENTA's control so it makes sense they would focus on them.